Less invasive heart valve fix vs. open surgery: which is better for High-Risk patients?

NCT ID NCT05261204

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 4 times

Summary

This study compares two procedures for severe aortic valve stenosis: transcatheter aortic valve implantation (TAVI), a less invasive approach, and standard open-heart surgery. It will follow 4,000 high-risk patients for up to 24 months to see which method leads to fewer deaths, hospitalizations for heart failure, and valve problems. The goal is to determine if TAVI is a safer or more effective option for this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcatheter aortic valve implantation (TAVI) device
What this could lead to
If TAVI proves better or equal to surgery, it could become the preferred option for high-risk patients, reducing recovery time and complications.
What could go wrong
This is an observational study, not a randomized trial, so results may be biased. TAVI carries risks like valve leakage or need for reoperation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2013

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with aortic valve stenosis with or without CAD who were symptomatic of congestive heart failure and unresponsive to medical therapy and who were eligible for mechanical intervention performed with the use of TAVI procedure or surgical aortic valve replacement. The severity of AVS was assessed by transthoracic echocardiography, performed using the European Society of Echocardiography criteria.

Ages

18 to 90 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals enrolled in TAVI arm were required to have the predicted risk of operative mortality was ≥ 15% and/or a STS score of ≥ 10. A candidate who did not meet the STS score criteria of ≥ 10 was included in the study if a peer review by at least two surgeon investigators concluded and documented that the patient's predicted risk of operative mortality was ≥ 15%. For all group Senile degenerative aortic valve stenosis with echocardiography derived criteria: mean gradient \> 40 mm Hg or jet velocity \> 4.0 m/s or an aortic valve area (AVA) of \< 0.8 cm2 (or AVA index \< 0.5 cm2/m2). Exclusion Criteria: * • Patients with evidence of an acute myocardial infarction ≤ 1 month before the intended treatment (defined as Q wave MI, or non-Q wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin level elevation. * Blood dyscrasias as defined : leukopenia (WBC \< 3000 mm3), acute anemia (Hb \< 9 mg%), thrombocytopenia (platelet count \< 50,000 cells/mm³), history of bleeding diathesis or coagulopathy. * Hemodynamic instability requiring inotropic therapy or mechanical hemodynamic support devices * Need for emergency surgery for any reason. * Hypertrophic cardiomyopathy with or without obstruction. * Severe ventricular dysfunction with LVEF \< 20%. * Echocardiographic evidence of intracardiac mass, thrombus or vegetation. * Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months. * A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel * (Plavix), or sensitivity to contrast media, which cannot be adequately pre-medicated. * For TAVI arm Native aortic annulus size \< 18mm or 25mm as measured by echocardiogram. * Subject was offered surgery but refused surgery. * Recent (within 6 months) cerebrovascular accident or transient ischemic attack. * Renal insufficiency (creatinine \> 3.0mg/dL) and/or end stage renal disease requiring chronic * dialysis. * Life expectancy \< 12 months due to non-cardiac co-morbid conditions. * For TAVI group significant abdominal or thoracic aorta disease, including aneurysm (defined as maximal luminal diameter 5 cm or greater), marked tortuosity, aortic arch atheroma, narrowing of the abdominal aorta with particular regard for calcification and surface irregularities, or severe "unfolding" and tortuosity of the thoracic aorta. This criteria were applicable for transfemoral patients only. * For TAVI group Iliofemoral vessel characteristics that would preclude safe placement of 14F or 18F introducer * For TAVI arm sheath such as severe calcification, severe tortuosity or vessels size diameter \< 7 mm for 22F * Active bacterial endocarditis or other active infections. * For TAVI arm bulky calcified aortic valve leaflets in close proximity to coronary ostia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis Prosthesis Failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Francesco Nappi

    Saint-Denis, France, 93200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.